If you or a loved one are taking Tysabri and concerned about PML, you're likely seeking clear answers about the risks. The scientific understanding of PML in Tysabri patients continues to evolve, but important evidence gaps remain. This page outlines the current evidence boundaries and what researchers have established so far.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV) and typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label identifies three risk factors that increase the likelihood of developing PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. Diagnosis is typically confirmed by brain MRI and detection of JCV DNA in cerebrospinal fluid. Because PML can be rapidly progressive and often leads to severe disability or death, early recognition is critical. The Tysabri label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, adverse event reports submitted to the FDA's FAERS database list PML-related symptoms among the most frequently reported events for Tysabri, including fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports underscore the importance of vigilance in monitoring patients on Tysabri.
The mechanistic pathway linking Tysabri to PML involves the drug's mechanism of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking the adhesion of immune cells to endothelial cells and thereby preventing their migration into the central nervous system. This immunosuppressive effect reduces inflammation in multiple sclerosis but also impairs immune surveillance against JCV, allowing the virus to reactivate and cause PML. The risk is particularly elevated in patients who are anti-JCV antibody positive, have received Tysabri for more than two years, or have a history of prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also notes that Tysabri increases the risk of herpes encephalitis and meningitis, with serious and sometimes fatal cases reported in the postmarketing setting (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients in Arizona who have developed PML after taking Tysabri, legal considerations may arise regarding the adequacy of warnings provided by the manufacturer. The boxed warning on the Tysabri label explicitly states the risk of PML and the need for enrollment in the TOUCH Prescribing Program, a restricted distribution program designed to ensure that patients are informed of the risks and monitored appropriately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may be raised about whether the warnings were sufficiently clear or timely, particularly for patients who developed PML before the boxed warning was updated or who were not adequately informed of their individual risk factors.
The statute of limitations for filing a product liability lawsuit in Arizona generally requires that a claim be brought within two years of the date the injury was discovered or should have been discovered. For PML, the timeline between exposure to Tysabri and documented harm can vary, but the label notes that PML has occurred in patients treated for a few months to several years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability may affect the calculation of the statute of limitations, as the date of discovery could be when symptoms first appeared or when a formal diagnosis was made. Patients affected by Tysabri-associated PML should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances, including the timing of exposure, diagnosis, and any potential failure to warn. The evidence from the FDA label and adverse event reports provides a factual basis for understanding the risks and the regulatory framework surrounding Tysabri. While the label includes warnings, the occurrence of PML despite these warnings may indicate that additional measures are needed to protect patients. In Arizona, the statute of limitations is a critical factor, and prompt legal advice is recommended to preserve the right to seek compensation for medical expenses, lost income, and pain and suffering.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Request archival records or inquire about member-exclusive transition and benefit programs.
In Arizona, the statute of limitations for product liability claims generally requires that a lawsuit be filed within two years from the date the injury was discovered or reasonably should have been discovered. For PML, this may be when symptoms first appear or when a formal diagnosis is made. It is crucial to consult an attorney promptly to preserve your rights.
According to the Tysabri prescribing information, the three main risk factors for PML are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.